Relapse of Visceral Leishmaniasis in an HIV-Infected Patient Successfully Treated with a Combination of Miltefosine and Amphotericin B by Shauna McQuarrie, Ken Kasper, Dana C Moffatt, Daniel Marko, Yoav Keynan

“…The high likelihood of relapse and response to combination therapy are illustrated.…”
Get full text

Case Study on Management of Overweight (Sthoulya) through Ayurveda by Ashvini D. Pardhekar, Shreya Satpute, Abhilash Pardhekar, Manisha Davkare

“…There was an improvement in subjective parameters, anthropometric measurements, body mass index (BMI), and body weight after treatment. The combination therapy comprising Tryushanadi Guggul, Udvartan with Vacha Churna, and Peti Sweda demonstrated effectiveness in improving the lipid profile and anthropometric measurements of the patient over a 30-day treatment period.…”
Get full text

TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC by Xiao-Mei Tang, Min-Min Shi, Jia-Cheng Wang, Yi-Jin Gu, Yu-Ting Dai, Qin-Xin Yang, Jia Liu, Ling-Jie Ren, Xin-Yun Liu, Chun Yang, Fang-Fang Ma, Ji-Bing Liu, Hong Yu, Da Fu, Yun-Feng Wang

“…In conclusion, TOPBP1 is a potential marker for optimizing the olaparib and AZD6738 combination therapy in PDAC. This study highlights the clinical significance of TOPBP1 in the treatment of PDAC and emphasizes the potential implications for a broader population of patients.…”
Get full text

Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors by Linan Yin, Ruibao Liu, Wei Li, Shijie Li, Xunbo Hou

“…Methods This retrospective study included 172 patients with uHCC who underwent combination therapy of TACE-HAIC with TKIs and PD-1 inhibitors. …”
Get full text

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis by Peter Youssef, Sabina Ciciriello, Talib Tahir, Joanna Leadbetter, Belinda Butcher, Miriam Calao, Nicole Walsh, Catherine O’Sullivan, Tegan Smith, Geoffrey Littlejohn

“…UPA monotherapy and combination therapy had similar persistence (27.8 [23.5, 33.4] versus 30.4 months [22.1, 35.3], p = 0.84) and effectiveness. …”
Get full text

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Ph... by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

“…Chemotherapy-free option lenvatinib plus anti-programmed cell death protein-1 (PD-1) combination therapy has shown promising results in several malignancies including ovarian cancer, but the toxicity of a high starting dose of lenvatinib is also notable and needs to be improved. …”
Get full text

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer by Shuailei Dong, Chen Wei, Xueting Wang, Xinyi Yang, Wei Shen, Shuyi Li, Jiye Xu, Yijie Ma, Liangyu Bie, Wenyue Yu, Ning Li

“…The median PFS was significantly longer in the combination-therapy (CT) group than in the MT group (5.3 versus 3.8 months, HR: 0.51, 95% CI: 0.31–0.85, p = 0.010), and the median OS was also notably increased (10.0 versus 6.8 months, HR: 0.45, 95% CI: 0.27–0.77, p = 0.003). …”
Get full text

Treatment of a schizophrenia patient on long-term super-dose antipsychotics: a case report by Xiaobo Xie, Jinzhang Chen, Hongli Song, Zebin Fan

“…The patient was followed for four years, during which his psychiatric symptoms remained under partial control.ConclusionClinicians must consider individual differences in the efficacy and adverse effects of antipsychotics and weigh the benefits and risks of combination therapy. Future efforts should focus on strengthening health education for patients with schizophrenia and their families to improve treatment compliance and outcomes.…”
Get full text

A case of cutaneous melanoma metastatic to the ciliary body and choroid with complete regression via systemic dual checkpoint inhibitor therapy by Ansam I. Qaddoumi, William I. Evans, Matthew W. Wilson

“…The metastatic ciliochoroidal lesion ultimately regressed completely with systemic dual checkpoint inhibitor therapy. Conclusion Combination therapy with ipilimumab and nivolumab immunotherapy may be effective in the treatment of aggressive intraocular metastatic cutaneous melanoma.…”
Get full text

Overcoming immune evasion with innovative multi-target approaches for glioblastoma by Hai Su, Yin Peng, Yilong Wu, Xiaoli Zeng, Xiaoli Zeng, Xiaoli Zeng

“…This review explores glioblastoma’s immune evasion mechanisms, the role of ICIs in the tumor microenvironment, and recent clinical advancements, offering theoretical insights and directions for monotherapy and combination therapy in glioblastoma management.…”
Get full text

Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation by Esin Oktay, Özlem Yersal, Nezih Meydan, Mehmet Sağıroğlu, Ömer Uyanık, Sabri Barutca

“…Trastuzumab treatment does not prevent intracranial seeding and is largely ineffective for established central nervous system metastasis in HER2 overexpressing breast cancer patients. Combination therapy of lapatinib and capecitabine may be an effective treatment option for brain metastasis of HER2-positive breast cancer. …”
Get full text

Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C by Yvette Leung, Stefan J Urbanski, Lynn Schindel, Robert P Myers

“…The present study describes the first case of ischemic colitis attributable to pegylated IFN-α and ribavirin combination therapy in an HCV-infected patient after 34 weeks of treatment. …”
Get full text

Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherap... by Cheng-Wei Huang, Ruo-Han Tseng

“…Herein, we report a patient with ovarian clear-cell carcinoma refractory to platinum-based chemotherapy, who was treated with a reduced dose of bevacizumab and pembrolizumab combination therapy and achieved a complete treatment response.…”
Get full text

Reproductive Late Effects in Female Survivors of Childhood Cancer by Shivany Gnaneswaran, Rebecca Deans, Richard J. Cohn

“…Patients who receive chemotherapy and/or ovarian radiation are at risk of premature ovarian failure; the risk increases with increasing radiation dose, alkylating agent score, combination therapy, and older age at treatment. Ovarian reserve may be assessed using antimullerian hormone assay and ultrasound measurements of ovarian volume and antral follicle count; however, their efficacy is poorly established in this cohort. …”
Get full text

Strategies to Overcome Antileishmanial Drugs Unresponsiveness by Shyam Sundar, Anup Singh, Om Prakash Singh

“…In the current review, we highlight various steps which could be implemented to halt the increasing unresponsiveness of drugs such as monitoring of therapy in the form of rational dosing and duration of treatment, understanding the mechanism of action of the drugs and drug resistance, identification of markers of resistance, distribution of drugs free of cost, evolution of effective combination therapy and immunotherapy, and proper management of HIV/VL coinfection and post-kala-azar dermal leishmaniasis (PKDL). …”
Get full text

Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat by Tamara Zenz, Robert Jenke, Denys Oliinyk, Sandra Noske, René Thieme, Tim Kahl, Ines Gockel, Florian Meier-Rosar, Achim Aigner, Thomas RH Büch

“…Moreover, our results provided the basis for combined entinostat + EGFR inhibitor (erlotinib) treatment, and indeed we demonstrate synergistic effects in combination therapy studies. Conclusion: Our findings establish the profound upregulation of the EGFR/AREG axis by entinostat as starting point for a rational combination therapy in gastric carcinoma.…”
Get full text

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat i... by Atsushi Nakajima, Takeharu Yamanaka, Koji Yamamoto, Yasushi Honda, Kento Imajo, Masato Yoneda, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, Satoru Saito, Michihiro Iwaki, Yusuke Saigusa, Haruki Usuda, Koichiro Wada

“…The patients will be randomly assigned to receive the combination therapy of 10 mg EXB and 9 g CTM powder (4 g CTM), 10 mg EXB monotherapy, 9 g CTM powder monotherapy or a placebo treatment (n=25 per group). …”
Get full text

Differences in the Treatment Response to Antithyroid Drugs versus Electroconvulsive Therapy in a Case of Recurrent Catatonia due to Graves’ Disease by Takahiro Saito, Rie Saito, Hiroshi Suwa, Fumiatsu Yakushiji, Kenji Takezawa, Mitsuru Nakamura

“…The patient showed different treatment response in each episodes; in the first episode, psychiatric and physical symptoms were resolved by a combination of antithyroid and anxiolytic therapies, while in the second episode, the combination therapy did not ameliorate her symptoms and ECT was indicated. …”
Get full text

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based... by Eric M Yoshida, Morris Sherman, Vincent G Bain, Curtis L Cooper, Marc Deschênes, Paul J Marotta, Samuel S Lee, Mel Krajden, Helga Witt-Sullivan, Robert J Bailey, Christopher Usaty, Kevork Peltekian, the Canadian Pegasys Study Group

“…BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. …”
Get full text

Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives by Akshyaya Pradhan, Monika Bhandari, Rishi Sethi

“…The drug has now established itself as an add-on therapy to statin when monotherapy fails to achieve LDL goals and when it is not tolerated. The combination therapy has excellent safety and efficacy record. …”
Get full text